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CBackground: Although for the great majority of indications, practice
guidelines recommend that antidepressants (ADs) be used for at least 6
months, premature discontinuation is very frequent in a “real-life” set-
ting. Previous studies have assessed the economic impact of such non-
persistence, but differences across antidepressant products remain in-
adequately explored. Objective: To compare treatment persistence
and incremental cost/persistence ratios (ICPRs) across individual new
ADs (selective serotonin reuptake inhibitors and atypical ADs) as well
as the associated direct health-care costs in the adult population cov-
ered by the public drug program of Quebec. Methods: A retrospective
ohort study was conducted in 13,936 adults aged 18 to 64 years who
tarted an AD treatment in 2003. Persistence was defined as treatment
uration of at least 6 months regardless of whether a product switch
ad occurred. Economic impact was assessed over the first year of
reatment through drug, medical services, hospitalization, and total
ealth-care costs. Comparisons across products were conducted using O
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oi:10.1016/j.jval.2010.11.015he ICPR. Results: Adjusting for confounders, treatment nonpersis-
ence ranged from 60.4% (paroxetine) to 65.1% (citalopram). The prod-
ct associated with the highest total health-care costs was citalopram
CDN$2653) and the lowest was venlafaxine (CDN$2168). Fluvoxamine
ad the lowest mean AD costs (CDN$215) and venlafaxine (CDN$309)
he highest. Conclusions: Total health-care costs were similar across
roducts except for citalopram, which was more costly. Comparisons
ased on the ICPR revealed that paroxetine, fluoxetine, and venlafaxine
ere more favorable than the other AD alternatives.
eywords: administrative claims databases, antidepressants, depres-
ion, pharmacoeconomics, pharmacoepidemiology, selective sero-
onin reuptake inhibitor.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Depression is one of the most frequent psychiatric disorders in the
general population [1–4], with more than half of depressed subjects
experiencing substantial functional impairment [3]. Lack of treat-
ment is associated with increased mortality, morbidity, use of
health-care services, institutionalization, and health-care costs [5–8].
Depression is increasingly considered as a relapsing-remitting ill-
ness and is a chronic disease. Risk of relapse or recurrence of symp-
toms has been associated with treatment duration [9,10], and evi-
dence has shown that a minimum treatment duration of 6 months is
required for a treatment to be effective [11,12]. For these reasons,
most clinical guidelines recommend that treatment of an incident
depressive episode be continued for at least 6 months, even if a
symptomatic improvement can be observed shortly after treatment
initiation [13]. If such guidelines were to be followed, the burden of
illness could be reduced by more than 25% [14].
However, in a community setting, treatment effectiveness is
ften compromised by early discontinuation of treatment [12,15–
* Address correspondence to:Yola Moride, Faculty of Pharmacy, Un
anada.
E-mail: yola.moride@umontreal.ca.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.7]. Furthermore, the “real-world” cost and relative effectiveness
f psychotropic medications remain poorly examined to date [18].
ccording to our previous study conducted in the elderly popula-
ion of Quebec (age 65), more than 50% of treatments are discon-
inued before 6 months, even when product switches occur [16].
he rate of discontinuation was recently estimated in the US adult
opulation, amounting to more than 40% after 30 days of treat-
ent and more than 70% after 90 days [19].
Although being equally efficacious as tricyclic antidepressants
TCAs), new antidepressants such as selective serotonin reuptake
nhibitors (SSRIs) (citalopram, fluoxetine, fluvoxamine, parox-
tine, sertraline) and serotonin-norepinephrine reuptake inhibi-
or (SNRI) (venlafaxine) have been shown to lead to fewer and less
erious adverse effects and hence are expected to be associated
ith better treatment persistence [20–22]. This hypothesis was
onfirmed in observational studies [23,24] and meta-analyses of
linical trials comparing SSRIs with TCAs [23,25]. Based on these
ndings, numerous practice guidelines recommend that when an
ntidepressant is to be prescribed in routine care, it should be an
ité de Montréal, C.P.6128, succ. Centre-ville, Montréal, QC, H3C 3J7
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
493V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 2 – 4 9 8SSRI [13]. On the other hand, safer products have led to an in-
creased number of users of new antidepressants and associated
costs [26,27]. In addition to the risk of relapse, suboptimal treat-
ment persistence results in important health-care costs, with an
estimated US$1000 per suboptimal treatment according to a re-
view of the literature conducted in 1998 [28]. In 2009, the GRACE
(Good ReseArch for Comparative Effectiveness) principles stated
that comparative effectiveness research is needed to support
treatment decisions by patients or physicians with respect to the
choice of treatment, to guide formulary decisions, and to inform
coverage policy decisions by payers [29]. Considering the diversity of
choices available in antidepressant treatment, comparative effec-
tiveness research appears to be a priority for this therapeutic area.
Furthermore, McGlynn et al. [18] stated that there is a pressing need
for comparative effectiveness research in mental health treatments.
Such a statement stems from the well-known gaps in mental health
care, as illustrated by a study among US patients that showed that
only one in four patients receive appropriate treatment [18].
Previous observational studies suggested that persistence with
antidepressant treatment is related to treatment effectiveness,
with adequate persistence resulting in a reduction in total health-
care costs [30]. Although the advantage of SSRIs over TCAs has
been established, few studies have attempted to compare the new
products with each other [31–36], with most studies considering
persistence only [37–41] or direct health-care costs only [42–44].
Our previous study conducted in the elderly population of Quebec
showed that 55.6% of antidepressant treatments were nonpersis-
tent, and paroxetine was associated with the lowest nonpersis-
tence rate (50.5%). In the elderly population of Quebec, overall
health-care costs can reach more than CDN$10,000 per year [36].
However, the economic impact of nonpersistence in the younger
adult population age 18 to 64 remains poorly examined, and re-
sults found in the literature appear somewhat conflicting.
Our study aimed to compare, in the community-dwelling adult
population age 18-64 of Quebec, new antidepressants with respect
to nonpersistence and associated health-care costs. More specifi-
cally, the objectives were to 1) compare nonpersistence across prod-
ucts prescribed at treatment initiation (regardless of whether the
product was subsequently switched); 2) assess the direct health-care
costs (antidepressants, other drugs, medical services, hospitaliza-
tions, total costs) over the first year after treatment initiation; 3) as-
sess the association between nonpersistence and direct health-care
costs; and 4) using persistence as an indicator of effectiveness, com-
pare the cost/persistence ratio (CPR) and the incremental CPR (ICPR)
across products. We considered treatment duration as a marker for
effectiveness because premature discontinuation is typically related
to adverse effects, absence of clinical or symptomatic benefits, or
poor management of the disease [45–46]. The minimum treatment
duration of 6 months remains true for the great majority of indica-
tions that require the use of antidepressants. Regardless of the rea-
son for discontinuation, nonpersistence is an indicator of treatment
failure and increases the risk of recurrence and relapse.
Patients and methods
Overview of the design
A retrospective fixed cohort study was conducted using the Quebec
public health-care databases of the Régie de l’assurance-maladie du
Québec (RAMQ), namely, 1) the prescription database of the public
drug reimbursement program (RAMQ prescription), 2) the medical
services database of the universal health-care program (RAMQ med-
ical services), and 3) the hospital discharge database (Med-Echo). For
the study, the target population consisted of adult patients who
started antidepressant treatment between January 2003 and April
2004. The antidepressants included citalopram, fluoxetine, fluvox-
amine, paroxetine, sertraline, and venlafaxine. Because they exhibitdifferent patterns of use or have been widely investigated in the lit-
erature, TCAs and trazodone were excluded from the study. Patients
were followed for 12 months after treatment initiation (index date).
Study population
The study population consisted of patients age 18 to 64 who were
incident users of new antidepressants and who met the following
inclusion criteria: 1) incident use, defined as absence of dispensings
of the antidepressants listed here in the 365 days before initiation of
current treatment (index date) and 2) member of the public drug
program of Quebec for at least 12 months before and after the index
date. Patients who died, changed their drug insurance program, left
Quebec, or were institutionalized over the follow-up period were ex-
cluded. Patients who were hospitalized during the week before the
index date were also excluded to avoid misclassification of the date
of treatment initiation and initial dose.
Data sources
Quebec residents who do not have access to private drug insur-
ance programs must be covered by the public program. The RAMQ
prescription database thus includes welfare recipients, the great
majority of elderly age 65, and all residents younger than 65
years of age who are self-employed or employed by small organi-
zations. Overall, the plan covers approximately 45% of the adult
population and their dependents and represents the middle class
population of the province. The database includes the following
information for each dispensing: age, sex, income level, physi-
cian’s specialty, and dose.
The RAMQ medical services program is universal, i.e., all resi-
dents are covered regardless of age or income. The database in-
cludes information on medical services that are billed on a fee-for-
service basis whether it was rendered in outpatient clinics,
emergency departments, or hospitals. Among the variables in-
cluded in the database are age, sex, income level, physician’s spe-
cialty, diagnosis, and type of service (medical act).
The Med-Echo database includes information on discharges
from the majority of acute care hospitals in the province. It in-
cludes information on age, sex, income level, physician’s spe-
cialty, and primary and secondary diagnoses.
The three databases may be linked through the health insur-
ance number, which is unique to each patient and remains un-
changed over time.
Study outcomes
The dependent variables for the study consisted of treatment non-
persistence, health-care costs, and cost-persistence ratio. Nonper-
sistence was defined as a treatment duration of less than 180 days,
determined from the patterns of dispensing in the RAMQ prescrip-
tion database [12]. Persistence was determined whether the same
product was maintained for the whole period or switched to an-
other product, consistent with an intent-to-treat approach. If the
same product was maintained throughout, total duration was the
sum of individual prescribed durations. If there was a product
switch, total duration was the sum of individual treatment dura-
tions minus the periods of overlap because it was assumed that
the change would occur immediately and that the patient would
not finish the treatment with the first product before switching.
Treatment was considered to be discontinued if there was no
other dispensing within 30 days after the end of the last dispens-
ing, during the first 6 months of treatment.
According to a third-party payer perspective, direct health-care
costs included cost of prescribed drugs (antidepressants and oth-
ers), which took into account dispensing fees as well as cost of
medical services and hospitalizations. Even if the main diagnosis
related to hospitalizations could be linked to a specific disease, all
hospitalizations were considered. All medical services and hospi-
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494 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 2 – 4 9 8talizations should be considered because somatization is very fre-
quent among depressive patients who often seek care for other
symptoms. All costs were quantified in Canadian dollars (CDN$),
without discounting as the time perspective was 1 year.
Independent variables and covariates
The main independent variable was the antidepressant prescribed at
treatment initiation (paroxetine, citalopram, venlafaxine, sertraline,
fluvoxamine, fluoxetine). Other variables that could influence non-
persistence were those identified in our previous studies [16,36].
They included physician specialty (general practitioner or specialist),
patient characteristics (i.e., age, sex, socioeconomic status, deter-
mined by the category of coverage in the drug program, which de-
pends on income), antidepressant dose considering achievement or
not of the recommended daily dose for maintenance treatment, his-
tory of antidepressant treatment with older treatments (such as
TCAs) during the year before the index date and during the follow-up
period, as well as overall health status quantified by the Chronic
Disease Score (CDS), which was obtained from prescription claims
data over the year before the index date [47]. In the CDS, scores as-
signed to the various drugs are weighted according to the probability
of death in the following year, hence, the higher the overall score, the
poorer the health status of the patient.
Statistical analysis
Multivariate logistic regression analyses were used to quantify the
association between the probability of nonpersistence and the prod-
uct, adjusting for all the covariates listed here. Products were subse-
quently compared with respect to direct costs associated with anti-
depressant drugs, other medications, outpatient health services
Table 1 – Baseline characteristics of patients who started tr
venlafaxine in 2003 in Quebec according to product at trea
Citalopram
(n  3226)
Fluoxetine
(n  1905)
Fluvo
(n 
Age, years, mean (SD) 42.4 (13.4) 42.1 (13.0) 43.7
Female, no. (%) 2159 (66.9) 1299 (68.2) 650
Low economic status,
no. (%)
1228 (38.1) 645 (33.9) 421
Chronic disease score,
mean (SD)
1.5 (2.7) 1.1 (2.3) 1.2
Prescriber specialist,
no. (%)
511 (15.8) 512 (26.9) 245
Table 2 – Frequency of nonpersistence by antidepressant p
initiation*.
Freq
No. %* 95% CI‡
ITT
Difference
frequency fo
1/Paroxetine 2448 60.4 58.6–62.3 1  6;
2/Fluoxetine 1905 61.6 59.5–63.6
3/Fluvoxamine 1030 62.1 59.2–64.9
4/Venlafaxine 3080 63.7 62.0–65.3
5/Sertraline 2247 64.4 62.5–66.4 5 
6/Citalopram 3226 65.1 63.4–66.7 6 
CI, confidence interval; ITT, intent to treat; NA, not available; PP, per
* Nonpersistence regardless of product switch during first 6 months
† Nonpersistence according to initial product (PP).
‡ Adjusted for age, sex, income level, history of antidepressant treatmspecialist), dose.including emergency department visits, and hospitalizations over
the 12-month follow-up. Persistence was used as a proxy for effec-
tiveness. For every product, the CPR was defined as the average total
health-care cost per persistent treatment (i.e., total cost/total num-
ber of persistent treatments). The ICPR was calculated for every prod-
uct (i.e., total cost associated with the product total cost associated
with the reference product/ frequency of persistent treatments with
the product frequency of persistent treatments with the reference
roduct). Products were ranked according to the average persistence.
very product was compared to each other. Accordingly, the new
roduct (better persistence) comparison was always made using the
ost cost-effective product as the reference. The CPR and the ICPR
ere calculated pairwise with the total health-care costs (antide-
ressants cost, other medications, medical services, and hospitaliza-
ion costs). All analyses were conducted with SAS version 9.1 [48],
and the statistical level of significance was set at 0.05.
Ethical considerations
No patient or physician identifiers were provided to the research-
ers; only encrypted identifiers were used throughout the study.
The study was granted approval by Université de Montréal Re-
search Ethics Committee.
Results
Study population
A total of 13,936 patients who initiated antidepressant treatment
with a new antidepressant product in 2003 met the inclusion cri-
ent with a selective serotonin reuptake inhibitor or
t initiation.
ne
)
Paroxetine
(n  2448)
Sertraline
(n  2247)
Venlafaxine
(n  3080)
P value
) 41.9 (13.2) 43.0 (13.3) 41.9 (12.8) 0.001
) 1526 (62.3) 1497 (66.6) 1988 (64.6) 0.001
) 962 (39.3) 807 (35.9) 1075 (34.9) 0.001
1.3 (2.4) 1.3 (2.4) 1.2 (2.3) 0.001
) 291 (11.9) 387 (17.2) 444 (14.4) 0.001
ct and increasing order of persistence at treatment
cy of nonpersistence
ween
method
%† 95% CI
‡PP
Difference between
frequency for PP method
71.9 70.3–73.6 1  4, 6
70.7 68.8–72.6 2  4, 6
72.3 69.7–74.8 3  4
76.4 75.0–77.9 4  1, 2, 3
73.4 71.7–75.2 NA
75.9 74.4–77.3 6  1, 2
col.
atment (ITT).
Chronic Disease Score, physician’s specialty (general practitioner oreatm
tmen
xami
1030
(13.2
(63.1
(40.9
(2.5)
(23.8rodu
uen
bet
r ITT
1  5
1
1
proto
of tre
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495V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 2 – 4 9 8teria. Of those, 9119 were women (65.4%) and the mean age was
42.4 years (SD 13.4). Products dispensed at treatment initiation
were distributed as follows: 3226 (23.1%) with citalopram, 3080
(22.1%) with venlafaxine, 2448 (17.6%) with paroxetine, 2247
(16.1%) with sertraline, 1905 (13.7%) with fluoxetine, and 1030
(7.4%) with fluvoxamine. Differences in patient characteristics
across products are presented in Table 1. Mean age and sex distri-
bution differed across products. Conversely, the CDS was slightly
higher in subjects initiating treatment with citalopram than with
the other products, indicating a poorer overall health status (mean
CDS 1.51, (SD 2.68). Compared to other products, treatments initi-
ated with fluoxetine and fluvoxamine appeared more likely to be
prescribed by a specialist than a general practitioner.
Nonpersistence
The overall treatment nonpersistence was estimated at 63.2%, rang-
ing from 60.4% for paroxetine (95% confidence interval [CI] 58.6%–
62.3%) to 65.1% for citalopram (95% CI 63.4%–66.7%). Differences in
frequency of nonpersistence changed slightly after adjustment for
patient characteristics and physician specialty (Table 2).
Medical costs during the year following treatment initiation
Considering all new antidepressants, the overall medical costs
for the year after treatment initiation were estimated to be
CDN$2362 (95% CI CDN$$2285–CDN$2439). Antidepressant costs,
other drug costs, medical services costs, and hospitalization costs
accounted for, respectively, 10.5% (CDN$249, 95% CI CDN$245–
CDN$254), 33.7% (CDN$796, 95% CI CDN$753–CDN$839), 21.2%
(CDN$501, 95% CI CDN$488–CDN$514), and 34.5% (CDN$816, 95%
CI CDN$769–CDN$862) of the total costs.
Adjusting for the covariates listed here, the product associated
with the highest total cost was citalopram and the lowest was ven-
Table 3 – Costs (in Canadian dollars) over the year after tre
Antidepressants
Mean 95% CI Difference for
antidepressant costs
1/Citalopram 217 209–225 1  2, 4, 6
2/Fluoxetine 244 234–254 2  1, 3, 5; 2  4, 6
3/Fluvoxamine 215 201–229 3  2, 4, 6
4/Paroxetine 274 265–283 4  1, 2, 3, 5; 4  6
5/Sertraline 222 212–231 5  2, 4, 6
6/Venlafaxine 309 301–317 6  all
CI, confidence interval.
* Adjusted for age, sex, income level, history of antidepressant treat
specialist), and dose.
Table 4 – Incremental cost/persistence ratios (in Canadian
Antidepressants Total
costs
Total costs
persistence
(1  nonpersistence) Citalopram
2653
34.9
Citalopram 2653 34.9
Sertraline 2348 35.6 dom.
Venlafaxine 2168 36.3 dom.
Fluvoxamine 2405 37.9 dom.
Fluoxetine 2193 38.4 dom.
Paroxetine 2347 39.6 dom.dom., dominated.lafaxine. Considering each type of costs individually revealed other
differences across products: fluvoxamine had the lowest mean anti-
depressant costs (CDN$215, 95% CI CDN$201–CDN$229) and venla-
faxine the highest (CDN$309, 95% CI CDN$301–CDN$317). Venlafax-
ine was associated with the lowest mean costs of drugs other than
antidepressants (CDN$636, 95% CI CDN$581–CDN$692) and fluvox-
amine with the highest (CDN$954, 95% CI CDN$793–CDN$1114). Flu-
oxetine had the lowest mean costs of medical services (CDN$473,
95% CI CDN$442–CDN$505) and citalopram the highest (CDN$559,
95% CI CDN$526–CDN$591). The lowest mean hospitalization costs
were observed with fluoxetine (CDN$702, 95% CI CDN$601–CDN$803)
and the highest with citalopram (CDN$970, 95% CI CDN$849–
CDN$1091) (Table 3).
ICPRs
All products were ranked according to their decreasing nonpersis-
tence (i.e., increasing persistence). Table 4 shows that the product
with less persistence is the citalopram with 34.9% of patients who
persisted with the treatment compared to the product that led to a
greater persistence, paroxetine, with a percentage of persistence
of 39.6%. Considering all health-care costs and comparing each
product against each other, citalopram, fluvoxamine, and sertra-
line were outclassed by the other products. When considering to-
tal costs, these products were more expensive and less effective,
as shown by poorer persistence, than venlafaxine, fluoxetine, and
paroxetine (Table 4). The ICPRs were calculated with this for-
mula: differences of costs between two products/differences of
persistence between the same two products. For example, ci-
talopram is dominated by sertraline because costs are higher
and persistence is less. It would say that citalopram is not a
cost-effective treatment. If we look at the comparison of fluox-
etine and paroxetine (the two products with the better persis-
nt initiation*.
Other drugs Medical services Hospitalization
ean 95% CI Mean 95% CI Mean 95% CI
911 831–991 559 526–591 970 849–1091
769 687–852 473 442–505 702 601–803
954 793–1114 487 438–536 746 596–896
782 619–945 495 465–525 803 696–909
815 717–913 483 451–515 830 709–952
636 581–692 480 455–504 747 663–831
, Chronic Disease Score, physician specialty (general practitioner or
rs) for total costs.
Antidepressants
raline Venlafaxine Fluvoxamine Fluoxetine Paroxetine
348 2168 2405 2193 2347
5.6 36.3 37.9 38.4 39.6
om.
25 148
om. 12 dom.
om. 54 dom. 128atme
M
mentdolla
Sert
2
3
d
d
d
r
v
496 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 2 – 4 9 8tence rates), it will cost CDN$12,800 to have one patient be more
persistent. Figure 1 presents a graphic interpretation of these
esults. It can be seen that, except for citalopram, products are
ery close and the confidence intervals overlap.
Switch between products
Table 5 shows the percentage of persistent patients who switch
drugs during their treatment. The percentage of patients who
switched is very low (between 9% and 13%). The first choice of
product for the switch was the trazodone, which can be ex-
plained by the fact that trazodone is known to have fewer anti-
cholinergic and fewer adrenolytic adverse events. Table 5 also
shows that tricyclics or tetracyclics are rarely used for a second
indication. In addition, Table 5 shows that in the majority of
cases, the time before the switch is 30 days, which can be ex-
plained by the fact that the period with the higher probability of
adverse events is the first 30 days of use.
Discussion
Our study confirmed results from previous studies [12,15,17,19,36]
that 6-month persistence with antidepressant treatment is low in
adults. The lowest persistence was observed with treatments ini-
tiated with citalopram, with fewer than 4 of 10 patients having an
adequate duration (34.9%, 95% CI 33.3%–36.6%). These results
greatly compromise the effectiveness of these products in a real-
life setting. However, being a first-line treatment, citalopram is
Fig. 1 – Mean total costs and effectiveness of alternative
antidepressant treatment.
Table 5 – Percentage of patients who switched from one an
% ISRS,
%
Treatment
option
Citalopram 10.8 25.60 Sertraline
Sertraline 9.0 22.30 Citalopram
Venlafaxine 12.7 39.80 Citalopram
Fluvoxamine 10.2 32.40 Citalopram
Fluoxetine 9.1 31.70 Citalopram
Paroxetine 11.5 33.30 Citalopram
* More prevalent treatment.
† Even if a treatment was not retained as first intention, it has been retainfrequently prescribed for patients with comorbidities and more
severe depression. Also, as shown in Table 5, citalopram is fre-
quently prescribed when a first antidepressant does not work well,
which can explain that persistence is lower with that product. A
selection bias, also called the immeasurable time bias, may be
introduced if these patients were hospitalized more before entry
in the cohort. Compared to the other products, paroxetine and
sertraline are associated with more favorable treatment persis-
tence. Furthermore, antidepressant use has increased dramati-
cally over the past 15 years, and costs associated with antide-
pressant drugs have nearly tripled between 1993 and 1997 in
Canada. The proportion of premature discontinuation associ-
ated with new products is much higher than that observed in
clinical trials or meta-analyses, which emphasizes the impor-
tance of conducting postmarketing studies to evaluate the ef-
fects of drugs in a real-life setting. In a real-life setting, better
persistence could result in less need for medical resources be-
cause of relapse, symptom recurrence, or occurrence of side
effects. We were unable to determine the reasons for treatment
discontinuation. Without data on reasons for medical consulta-
tions or hospitalizations, for instance, these hypotheses remain
speculative and would need to be investigated in further stud-
ies. However, these results emphasize the fact that close fol-
low-up by physicians is recommended to increase the persis-
tence of antidepressant treatment. Clinical guidelines or
recommendations for the follow-up of patients using antide-
pressants are needed.
In our study, significant differences were found across prod-
ucts in both treatment persistence and costs. These results con-
tradict those of clinical trials and other studies in which no
difference in efficacy among the individual SSRIs or between
SSRIs as a group and TCAs or other antidepressants [48 –53]. It is
well-known, however, that randomized, controlled trials are
conducted in an optimal setting, and it is normal to see better
persistence than in a real-life setting. Interestingly, in our
study, the ICPR calculated for total health-care costs associated
with antidepressant use shows that favorable results were ob-
tained by initiating treatments with paroxetine, fluoxetine, and
venlafaxine, but not with the other products. Because ICPR es-
timation is an incremental procedure, this could mean that the
benefit of persistence obtained by initiating antidepressant
treatments with fluoxetine or paroxetine instead of venlafaxine
would be cost-effective if we are willing to pay, respectively,
CDN$12 and CDN$54 for a 1% increase in treatment persistence.
However, initiating such treatments with the other SSRIs in-
stead of paroxetine, fluoxetine, and venlafaxine would not be
cost-effective, if we consider all health-care costs. Because per-
sistence is an indicator of treatment effectiveness, CDN$54 ap-
pears to be acceptable to minimize the consequences of depres-
pressant to another class of antidepressant.
Tetra,
%
Treatment
option*
Others,
%†
Treatment
option*
9.40 Amitriptyline 65.00 Trazodone
1.40 Amitriptyline 76.40 Trazodone
8.30 Amitriptyline 51.90 Trazodone
1.40 Amitriptyline 66.20 Trazodone
0.80 Amitriptyline 67.50 Trazodone
4.50 Amitriptyline 62.10 Trazodonetide
Tri-ed as a second intention.
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antidepressant treatment.
We were not able, among all health-care costs, to identify those
related to depression. This is a limitation of our study that hampers
the ability to associate cost estimates with the economic burden of
depression. Furthermore, confounding by indication bias may be
present because it is well-known that citalopram is prescribed more
frequently for patients in poorer health, which can explain the low
persistence with this product. Also, because of the structure of the
database, it was impossible to take into account the status of the
depression (mild, moderate, or severe). Nevertheless, the study fo-
cused on treatment and not on indication because the majority of
indications for the use of antidepressants do require at least 6
months of treatment (e.g., generalized anxiety) [51]. Also, for the sta-
tus of depression, we attempt to control for the severity of the disease
by using an instrumental variable: the prescriber specialty. In addi-
tion, to only consider depression-related health services use would
result in an underestimation of the real costs of depression because
of depressed patients who somatize and present to their doctor with
a somatic symptom, which makes patients seek care for another
reason [5]. Furthermore, because all our analyses were adjusted for
economic status (income level) and the CDS, the assumption that
differences in the adjusted health-care costs are mostly related to
depression costs seems reasonable. There are other limitations of
this study. Some medical services and hospitalization costs, like phy-
sician services paid on a salary basis or some hospitalizations, may
not be included in the RAMQ or Med-Echo databases. This bias could
lead to an underestimation of health-care costs. However, there are
no reasons to believe that this bias is differential across antidepres-
sant products, and it can be assumed that it will not have a major
impact on product comparisons. Indications may vary across prod-
ucts, although a study has shown that indications were similar for
newer antidepressants [52]. Patient characteristics were also very
imilar across products. On the other hand, prescriber specialty dif-
ered, which may reflect differences in the nature or seriousness of
he depression, and may be responsible for differences in health-care
osts instead of differences in treatment effectiveness. To minimize
he possibility of such indication bias (one treatment being associ-
ted with the highest costs because it is selectively prescribed for
ore serious cases), analyses were adjusted for prescriber specialty.
evertheless, the possibility of a residual confounding cannot be
uled out [50] because data on severity were not available from claims
atabases.
Conclusion
Although differences in persistence across treatments were mod-
est (5% difference between the best and worse product), the eco-
nomic impact is important because most of the costs are not re-
lated to the antidepressants but to more costly services such as
hospitalizations and medical services. Paroxetine appears to be a
good choice with the lowest nonpersistence and a CDN$1283.33
ICPR compared to fluoxetine, the option with the second highest
persistence. However, our results showed that switch rate is lower
in the fluoxetine users. The most important finding of this study is
that there is evidence that treatment persistence is very low for all
treatment. Interventions targeted at persistence, such as disease
management programs, would likely result in an improvement in
the cost-effectiveness of these products in real life. Also, there is
an important need for the development of clinical guidelines for
the follow-up of patients using antidepressants.
Source of financial interest: Study funded by the Conseil du
Médicament/Fonds de la recherche en santé du Québec (FRSQ).
[R E F E R E N C E S
[1] Beaudet MP. Depression. Health Rep 1996;7:11–25.
[2] Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major
depressive disorder: results from the National Epidemiologic Survey
on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62:
1097–106.
[3] Kessler RC, Berglund P, Demler O, et al. The epidemiology of major
depressive disorder: results from the National Comorbidity Survey
Replication (NCS-R). JAMA 2003;289:3095–105.
[4] Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and
comorbidity of 12-month DSM-IV disorders in the National
Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617–27.
[5] Alexopoulos GS. Depression in the elderly. Lancet 2005;365:1961–70.
[6] Alexopoulos GS, Kiosses DN, Heo M, et al. Executive dysfunction and
the course of geriatric depression. Biol Psychiatry 2005;58:204–10.
[7] Fischer LR, Wei F, Rolnick SJ, et al. Geriatric depression, antidepressant
treatment, and healthcare utilization in a health maintenance organization.
J Am Geriatr Soc 2002;50:307–12.
[8] Flint AJ, Rifat SL. Two-year outcome of elderly patients with anxious
depression. Psychiatry Res 1997;66:23–31.
[9] Geddes JR, Carney SM, Davies C, et al. Relapse prevention with
antidepressant drug treatment in depressive disorders: a systematic
review. Lancet 2003;361:653–61.
[10] Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute
major depression and dysthymia. American College of Physicians-
American Society of Internal Medicine. Ann Intern Med 2000;132:738–
42.
[11] Klerman GL, Weissman MM. The course, morbidity, and costs of
depression. Arch Gen Psychiatry 1992;49:831–4.
[12] Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to
antidepressant treatment guidelines on relapse and recurrence of
depression. Arch Gen Psychiatry 1998;55:1128–32.
[13] National Institute for Clinical Excellence. Depression: management of
depression in primary and secondary care, clinical guideline 23
(amended). 2004 April 25, 2007 [cited March 16, 2008]; Available from:
http://www.nice.org.uk:80/guidance/index.jsp?actiondownload&o
29615. [Accessed July 13, 2010].
[14] Vos T, Haby MM, Barendregt JJ, et al. The burden of major depression
avoidable by longer-term treatment strategies. Arch Gen Psychiatry
2004;61:1097–103.
[15] Katon W, von Korff M, Lin E, et al. Adequacy and duration of
antidepressant treatment in primary care. Med Care 1992;30:67–76.
[16] Moride Y, Du Fort Galbaud du Fort G, Monette J, et al. Suboptimal duration of
antidepressant treatments in the older ambulatory population of Quebec:
association with selected physician characteristics. J Am Geriatr Soc 2002;
50:1365–71.
17] Simon GE, VonKorff M, Wagner EH, Barlow W. Patterns of
antidepressant use in community practice. Gen Hosp Psychiatry 1993;
15:399–408.
18] McGlynn, EA, et al. The quality of health care delivered to adults in
the United States. N Engl J Med 2003;348:2635–45.
19] Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of
antidepressant treatment for adults with depression in the United
States. Am J Psychiatry 2006;163:101–8.
20] Moller HJ, Gallinat J, Hegerl U, et al. Double-blind, multicenter
comparative study of sertraline and amitriptyline in hospitalized
patients with major depression. Pharmacopsychiatry 1998;31:170–7.
21] Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated
with selective serotonin reuptake inhibitors and tricyclic
antidepressants: a meta-analysis. CMAJ 1998;159:1245–52.
22] Wilson K, Mottram P. A comparison of side effects of selective
serotonin reuptake inhibitors and tricyclic antidepressants in older
depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004;19:
754–62.
23] Dobrez DG, Melfi CA, Croghan TW, et al. Antidepressant treatment for
depression: total charges and therapy duration. J Ment Health Policy
Econ 2000;3:187–97.
24] Fairman KA, Teitelbaum F, Drevets WC, et al. Course of
antidepressant treatment with tricyclic versus selective serotonin
reuptake inhibitor agents: a comparison in managed care and fee-for-
service environments. Am J Manag Care 1997;3:453–65.
25] Montgomery SA, Henry J, McDonald G, et al. Selective serotonin
reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin
Psychopharmacol 1994;9:47–53.
26] Hemels ME, Koren G, Einarson TR. Increased use of antidepressants in
Canada: 1981–2000. Ann Pharmacother 2002;36:1375–9.
27] Mamdani MM, Parikh SV, Austin PC, Upshur RE. Use of
antidepressants among elderly subjects: trends and contributing
factors. Am J Psychiatry 2000;157:360–7.28] Crott R, Gilis P. Economic comparisons of the pharmacotherapy of
depression: an overview. Acta Psychiatr Scand 1998;97:241–52.
[[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
498 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 2 – 4 9 8[29] Dreyer, N.A. GRACE principles: Good ReseArch for Comparative
Effectiveness OBSERVED. 2009. Available from: www
.graceprinciples.org. [Accessed July 21, 2010].
30] Sheehan DV, Eaddy MT, Shah MB, Mauch RP. Differences in total
medical costs across the SSRIs for the treatment of depression and
anxiety. Am J Manag Care 2005;11(Suppl. 12):S354–61.
31] Monfared AA, Han D, Sheehy O, et al. Assessment of Canadian
provincial expenditures in depressed patients treated with
venlafaxine XR versus SSRIs: the APEX Study. Curr Med Res Opin 2006;
22:83–94.
32] Wan GJ, Crown WH, Berndt ER, et al. Treatment costs of
venlafaxine and selective serotonin-reuptake inhibitors for
depression and anxiety. Manag Care Interface 2002;15:24 –30.
33] Crown WH, Treglia M, Meneades L, White A. Long-term costs of
treatment for depression: impact of drug selection and guideline
adherence. Value Health 2001;4:295–307.
34] Polsky D, Onesirosan P, Bauer MS, Glick HA. Duration of therapy and
health care costs of fluoxetine, paroxetine, and sertraline in 6 health
plans. J Clin Psychiatry 2002;63:156–64.
35] Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for
depression with fluoxetine, paroxetine, and sertraline. Am J Manag
Care 1999;5:597–606.
36] Tournier M, Moride Y, Crott R, et al. Economical impact of non-
persistence to antidepressant therapy in the Quebec community-
dwelling elderly population. J Affect Disord 2008;115:160–6.
37] Johnsrud MT, Crismon ML. Economic evaluation of citalopram use and
expenditures among recipients in the Texas Medicaid program. J
Manag Care Pharm 2002;8:492–8.
38] Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine,
fluoxetine, sertraline and paroxetine examined by observational
cohort studies. Pharmacoepidemiol Drug Saf 1997;6:235–46.
39] Mullins CD, Shaya FT, Meng F, et al. Comparison of first refill rates
among users of sertraline, paroxetine, and citalopram. Clin Ther 2006;
28:297–305; discussion 296.
40] Mullins CD, Shaya FT, Meng F, et al. Persistence, switching, and
discontinuation rates among patients receiving sertraline, paroxetine,
and citalopram. Pharmacotherapy 2005;25:660–7.[41] Sheffield RE, Lo Sasso AT, Young CH, Way K. Selective serotonin
reuptake inhibitor usage patterns as risk factors for hospitalization.
Adm Policy Ment Health 2002;30:121–39.
[42] Hylan TR, Buesching DP, Tollefson GD. Health economic evaluations
of antidepressants: a review. Depress Anxiety 1998;7:53–64.
[43] Panzarino PJ Jr, Nash DB. Cost-effective treatment of depression with
selective serotonin reuptake inhibitors. Am J Manag Care 2001;7:173–
84.
[44] McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysis
comparing citalopram with sertraline as initial pharmacotherapy for a
new episode of depression: impact on depression-related treatment
charges. Clin Ther 2004;26:115–24.
[45] Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching
selective serotonin-reuptake inhibitors. Ann Pharmacother 2002;36:
578–84.
[46] Lin EH, Von Korff M, Katon W, et al. The role of the primary care
physician in patients’ adherence to antidepressant therapy. Med Care
1995;33:67–74.
[47] Von Korff M, Wagner EH, Saunders K. A chronic disease score from
automated pharmacy data. J Clin Epidemiol 1992;45:197–203.
[48] Allison, PD. Logistic regression using the SAS system – Theory and
application. Cary, NC: SAS Institute, Inc; 1999.
49] Office Canadien de Coordination de l’Evaluation des Technologies de
la Santé. Evaluation clinique et économique des inhibiteurs
spécifiques du recaptage de la sérotonine dans les cas de dépression
grave. Ottawa: OCCETS; 1998.
50] Edwards JG, Anderson I. Systematic review and guide to selection of
selective serotonin reuptake inhibitors. Drugs 1999;57:507–33.
51] National Institute for Clinical Excellence, management of general
anxiety disorders in primary care, 2008. November 20, 2008. Available
from: http://www.nice.org.uk/nicemedia/pdf/CG22AlgorithmGen
AnxietyDisorder.pdf. [Accessed July 20, 2010].
52] Lawrenson RA, Tyrer F, Newson RB, Farmer RD. The treatment of
depression in UK general practice: selective serotonin reuptake
inhibitors and tricyclic antidepressants compared. J Affect Disord
2000;59:149–57.
53] Wang PS, Ulbricht CM, Schoenbaum M. Improving mental health
treatments through comparative effectiveness research. Health
Affairs 2009;28:783–91.
